Pretransplant desensitization of donor-specific anti-HLA antibodies - Hunter Cochran (Washington University in St. Louis / Barnes-Jewish Hospital) #PretransplantDesensitization #AntiHLA #OncoDaily #Oncology #Cancer #MedicalResearch
OncoDaily’s Post
More Relevant Posts
-
Drug list Ver 3 for mNSCLC: 1st line EGFR common mutations EGFR Positive Lung Cancer UK American Society of Clinical Oncology (ASCO) #InkFactory #KCRS24 #KidneyCAN #OncoDaily #Oncology #Cancer #CancerPrevention
Drug list Ver 3 for mNSCLC: 1st line EGFR common mutations - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1- Benedetta Pellegrino University of Parma #BreastAndOvarianCancer #Cancer #OncoDaily #Oncology #CancerCare
Benedetta Pellegrino: Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1 - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
My very first full paper is published: The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance - Marissa Li Mayo Clinic American Society of Hematology https://lnkd.in/gpH2UFjh #oncodaily #oncology #cancer #research #cytopenia #cytotoxictherapy
Marissa Li: My very first full paper is published: The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Precision Medicine advocate and Personalized Healthcare early adopter | +15y of Commercial and Market Development Leadership experience | Medical Device, Companion Diagnostics (CDx) and IVD expert
Survival outcomes on CDK4/6 inhibitors from two trials - based on intrinsic subtypes https://lnkd.in/dsH5fT2e 2nd generation Genexpression tests can generate clinical insights.
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies - npj Breast Cancer
link.springer.com
To view or add a comment, sign in
-
Comprehensive review summarizing current clinical data on PARP inhibitors in gBRCA1/2 #breastcancer and some future considerations.
PARP Inhibitors for Breast Cancer Treatment
jamanetwork.com
To view or add a comment, sign in
-
NSCLC and anti-EGFR treatments from the ASCO Educational Book - Erman Akkus, MD American Society of Clinical Oncology (ASCO) #ADAURA #ADAURA2 #AnkaraUniversity #AntiEGFRTreatments #ASCO #Cancer #NonSmallCell #LungCancer #NSCLC #OncoDaily #Oncology
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Publication Alert: Article Publishes in Protein and Peptide Letters-Impact factor: 1.8
A review article on peptide dendrimer Thanks to Dr. Dilpreet Singh and team.
Guanidinium-based Integrated Peptide Dendrimers: Pioneer Nanocarrier in Cancer Therapy
eurekaselect.com
To view or add a comment, sign in
-
Patient-driven Biologist | Enthusiastic Translational Scientist | Experienced Drug Developer | Lifetime Learner | Project Leader | Team Player
Tyrosine kinase inhibitors (TKIs) targeted therapy have improved NSCLC clinical outcome, however, are limited by acquired resistance. These authors interrogated the dynamics of TKIs anti-tumor and its resistance mechanism in tumor microenvironment (TME). Short term TKI boost immunity by improving T cell-mediated tumor clearance and reducing M2 macrophages, however, long term TKIs lead to immunosuppression. Additional drug screening identified Aspirin as an adjunct therapy improved TKIs effectiveness by overcoming resistance. This paper supports the idea that easily-applied therapy, such as aspirin, helps overcome long term TKIs resistance in NSCLC. https://lnkd.in/eCzvuu9q
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect
jitc.bmj.com
To view or add a comment, sign in
-
Using cytometry by time of flight (CyTOF) technology, researchers measure multiple parameters for comprehensive cell phenotyping and functional analyses. This capability is especially important during drug development and efficacy testing when investigating disease pathways, drug targets, molecular mechanisms, and drug responses. Read on to learn how scientists use CyTOF to develop therapies for cancer, inflammatory diseases, and beyond in this new eBook from Standard BioTools. #AD https://ow.ly/5UkU50Rv7TP
Supporting Drug Development with CyTOF Technology
the-scientist.com
To view or add a comment, sign in
-
National Cancer Institute (NCI) is supporting research to better understand and manage cancer-related pain #Cancer #CancerCare #NationalCancerInstitute #NCI #OncoDaily #Oncology
NCI is supporting research to better understand and manage cancer-related pain - OncoDaily
oncodaily.com
To view or add a comment, sign in
25,911 followers